. Author manuscript; available in PMC: 2011 Apr 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2009 Dec 2;16(4):525–532. doi: 10.1016/j.bbmt.2009.11.020

Table 4.

Univariate probabilities of outcomes of subjects who underwent autologous transplantation for Rhabdomysarcoma, between 1989 and 2003, reported to the CIBMTR.

Outcome of interest	N (eval)	Probability (95% CI)
ANC>0.5 × 10⁹/L^a @ 28 days	62	97 (91–100) %
Platelet recovery ≥ 20 × 10⁹/L^a @ 28 days	58	50 (37–63) %
Transplant-related mortality^a	62
@ 1 year		5 (1–12) %
@ 3 years		8 (3–17) %
@ 5 years		8 (3–17) %
Progression/relapse^a	62
@ 1 year		59 (47–71) %
@ 3 years		63 (50–75) %
@ 5 years		63 (50–75) %
Progression free survival^b	62
@ 1 year		36 (24–48) %
@ 3 years		29 (18–41) %
@ 5 years		29 (18–41) %
Overall survival^b	62
@ 1 year		56 (43–68) %
@ 3 years		39 (28–52) %
@ 5 years		32 (21–44) %

Probabilities of relapse, treatment-related mortality, platelet & neutrophil engraftment were calculated using the cumulative incidence function

Probabilities of overall survival and progression free survival were calculated using the Kaplan-Meier product limit estimate.